Italian survey on managing immune checkpoint inhibitors in oncology during COVID‐19 outbreak
出版年份 2020 全文链接
标题
Italian survey on managing immune checkpoint inhibitors in oncology during COVID‐19 outbreak
作者
关键词
-
出版物
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-06-14
DOI
10.1111/eci.13315
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China
- (2020) Zunyou Wu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).
- (2020) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Testing for COVID-19 in lung cancer patients
- (2020) A. Passaro et al. ANNALS OF ONCOLOGY
- Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China
- (2020) L. Zhang et al. ANNALS OF ONCOLOGY
- COVID-19 infection: the perspectives on immune responses
- (2020) Yufang Shi et al. CELL DEATH AND DIFFERENTIATION
- Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management
- (2020) Ferdinando D’Amico et al. Clinical Gastroenterology and Hepatology
- A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
- (2020) Mallika Lala et al. EUROPEAN JOURNAL OF CANCER
- COVID‐19: focus on the lungs but do not forget the gastrointestinal tract
- (2020) Wiktor Smyk et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Reorganization of a large academic hospital to face COVID‐19 outbreak: The model of Parma, Emilia‐Romagna region, Italy
- (2020) Tiziana Meschi et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors
- (2020) Melissa Bersanelli Immunotherapy
- Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis
- (2020) Jing Yang et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy
- (2020) Giacomo Grasselli et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2020) Shirish Gadgeel et al. JOURNAL OF CLINICAL ONCOLOGY
- COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
- (2020) Lennard Y W Lee et al. LANCET
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
- (2020) Nicole M Kuderer et al. LANCET
- Cancer guidelines during the COVID-19 pandemic
- (2020) Talha Khan Burki LANCET ONCOLOGY
- Cytokine release syndrome in severe COVID-19
- (2020) John B. Moore et al. SCIENCE
- Challenges in lung cancer therapy during the COVID-19 pandemic
- (2020) Luana Calabrò et al. Lancet Respiratory Medicine
- SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China
- (2020) Jing Yu et al. JAMA Oncology
- Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature
- (2020) Nicola Veronese et al. Frontiers in Medicine
- Call for ensuring cancer care continuity during COVID-19 pandemic
- (2020) Marco Tagliamento et al. ESMO Open
- Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
- (2019) Y Fradet et al. ANNALS OF ONCOLOGY
- Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
- (2019) Yucai Wang et al. JAMA Oncology
- The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance
- (2019) Günther Schönrich et al. Frontiers in Cellular and Infection Microbiology
- 1310OAdjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
- (2019) J S Weber et al. ANNALS OF ONCOLOGY
- Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
- (2019) Jhanelle E. Gray et al. Journal of Thoracic Oncology
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer
- (2018) G V Long et al. ANNALS OF ONCOLOGY
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- A catalogue of reporting guidelines for health research
- (2009) I. Simera et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started